Tg Therapeutics (TGTX) Invested Capital (2010 - 2026)

Tg Therapeutics' Invested Capital history runs 17 years deep, the most recent figure standing at $583.1 million for Q1 2026.

• In Q1 2026, Invested Capital rose 145.75% year-over-year to $583.1 million; the TTM figure through Mar 2026 stood at $583.1 million (up 145.75% YoY), while the FY2025 annual figure was $648.0 million, up 191.42% from the prior year.
• Invested Capital was $583.1 million for Q1 2026 at Tg Therapeutics, down from $648.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $648.0 million in Q4 2025 to a low of $27.4 million in Q1 2023.
• Historically, Invested Capital has averaged $248.6 million across 5 years, with a median of $192.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Invested Capital plunged 83.9% in 2023, then jumped 483.64% in 2024.
• A 5-year view of Invested Capital shows it stood at $58.6 million in 2022, then surged by 345.33% to $260.9 million in 2023, then fell by 14.77% to $222.4 million in 2024, then soared by 191.42% to $648.0 million in 2025, then slipped by 10.01% to $583.1 million in 2026.
• The last three Invested Capital figures came in at $583.1 million (Q1 2026), $648.0 million (Q4 2025), and $607.2 million (Q3 2025), per Business Quant data.